Carlos D Núñez-Amaro, Mariana López, Elva Adán-Castro, Ma Ludivina Robles-Osorio, Renata García-Franco, Marlon García-Roa, Yolanda Villalpando-Gómez, Paulina Ramírez-Neria, Nayeli Pineiro, Juan Fernando Rubio-Mijangos, Jorge Sánchez, Gabriela Ramírez-Hernández, Lourdes Siqueiros-Márquez, Nundehui Díaz-Lezama, Ellery López-Star, Thomas Bertsch, Gonzalo Marínez de la Escalera, Jakob Triebel, Carmen Clapp
BACKGROUND/OBJECTIVE: The prokinetic levosulpiride elevates vasoinhibin levels in the vitreous of patients with proliferative diabetic retinopathy (PDR) suggesting clinical benefits due to the anti-vasopermeability and anti-angiogenic properties of vasoinhibin. We investigated the biological activity of levosulpiride in centre-involving diabetic macular oedema (DME). PATIENTS/METHODS: Prospective, randomized, double-blinded, dual-centre, phase 2 trial in patients with centre-involving DME orally treated with placebo (n = 17) or levosulpiride (n = 17) for 8 weeks or in patients with PDR undergoing elective pars plana vitrectomy and receiving placebo (n = 18) or levosulpiride (n = 18) orally for the 1 week before vitrectomy...
February 2024: Eye